The IWMF is pleased to announce that the U.S. FDA has approved the combination treatment of Imbruvica (ibrutinib) together with Rituximab (rituxan) for the treatment of WM.
Tom Hoffmann, MD, is the newest member of the Board of Trustees. His medical background and knowledge of WM will be of great benefit to the IWMF community.
Video for IWMF Website Visitors – Introducing the IWMF and its Services
Diagnosed with WM in 2015 at the age of 70, in 2016 he published two books of poetry, he is writing his third book and has two more in mind. ...
Cure Magazine recently published their Rare Cancers Special Issue, which contains an article focused specifically on WM and recent treatment advances for it.
Bob Rupert discusses how WM has affected him and his family and how he is living with the disease.
Peter DeNardis (diagnosed in 2003 at the age of 43) and his family discuss how WM has affected them, and how he’s chosen to live life fully despite the disease.
THE 5TH INTERNATIONAL PATIENT & PHYSICIAN SUMMIT ON WM
OCTOBER 13th & 14th, NEW YORK CITY, NEW YORK- USA
With an emphasis on WM, the IWMF 2018 Ibrutinib Fact Sheet explains how the drug is given, side effects, and self-care tips.
Videos of ALL main presentations from the 2018 IWMF Ed Forum (held in Rosemont, IL in May 2018) are now available, along with presentation slides and photos from the event.